<DOC>
	<DOC>NCT02021097</DOC>
	<brief_summary>The purpose of this study is to evaluate the contraceptive efficacy and safety of an oral contraceptive containing a combination of LNG 100mcg/EE 20mcg compared to LNG 150mcg/EE 30 mcg.</brief_summary>
	<brief_title>Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Healthy women,aged 2035 years who wish to use a contraceptive. Women without reproductive system infection complications. Willingness to not use other forms of hormonal treatment. Three regular menstrual cycles before the study(2135 days per cycle with 37 day's bleeding period, without amenorrhea or irregular bleeding). Signed informed consent prior to entry into the trial. Any contraindication to the use of oral contraceptives. Vascular, metabolic, hepatic, renal, oncologic and other diseases.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Levonorgestrel；</keyword>
	<keyword>Ethinyl Estradiol；</keyword>
	<keyword>Oral Contraceptive</keyword>
</DOC>